Pembrolizumab (+) Berahyaluronidase alfa clinical trials
4 indexed studies · 2 currently recruiting
- Active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
This study looks at a new way to give an existing medicine, pembrolizumab, for certain types of lymphoma. Instead of an IV, it's given as an injection under the skin, combined with another substance to help it spread. We want to see how well it works and if it's safe.
For: Classical Hodgkin Lymphoma Recurrent · Classical Hodgkin Lymphoma Refractory · Primary Mediastinal Large B-cell Lymphoma RecurrentUnited States · Australia · Chile - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
For: Solid Tumors · Hematologic MalignanciesUnited States · Argentina · Australia - Active not recruitingPHASE3
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
This study looks at a new way to give a lung cancer medicine called pembrolizumab. It compares giving it through a drip in your arm (IV) versus a new injection under the skin (SC) for people with advanced non-small cell lung cancer. Researchers want to see how the injection works.
For: Lung Cancer · Non-Small Cell Lung CancerUnited States · China · Germany - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia